Literature DB >> 9929010

Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor.

N Tanaka1, J Watanabe, T Kitamura, Y Yamada, S Kanegasaki, K Nakata.   

Abstract

Mice deficient in granulocyte-macrophage colony stimulating factor (GM-CSF) develop pulmonary alveolar proteinosis (PAP). We found that bronchoalveolar lavage fluid (BALF) from 11 patients with idiopathic pulmonary alveolar proteinosis (IPAP) suppressed the growth of peripheral blood monocytes and TF-1 cells, a cell line dependent on either GM-CSF or interleukin-3 (IL-3). The inhibitory effect of PAP-BALF occurred only when TF-1 cells were cultured with GM-CSF but not when cultured with IL-3, suggesting that PAP-BALF contains a factor that specifically interferes with GM-CSF function. 125I-GM-CSF binding to TF-1 cells was prevented in the presence of BALF from IPAP patients. Furthermore, cross-linking of 125I-GM-CSF to IPAP-BALF produced two major bands on SDS-PAGE; these bands were not observed in normal BALF. These data suggest that IPAP is caused by expression of binding factor(s) which inhibit GM-CSF function in the lung.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9929010     DOI: 10.1016/s0014-5793(98)01668-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  27 in total

1.  A cell free assay system estimating the neutralizing capacity of GM-CSF antibody using recombinant soluble GM-CSF receptor.

Authors:  Shinya Urano; Ryushi Tazawa; Takahito Nei; Natsuki Motoi; Masato Watanabe; Takenori Igarashi; Masahiro Tomita; Koh Nakata
Journal:  J Vis Exp       Date:  2011-06-27       Impact factor: 1.355

2.  Local GM-CSF-Dependent Differentiation and Activation of Pulmonary Dendritic Cells and Macrophages Protect against Progressive Cryptococcal Lung Infection in Mice.

Authors:  Gwo-Hsiao Chen; Seagal Teitz-Tennenbaum; Lori M Neal; Benjamin J Murdock; Antoni N Malachowski; Anthony J Dils; Michal A Olszewski; John J Osterholzer
Journal:  J Immunol       Date:  2016-01-11       Impact factor: 5.422

3.  Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates.

Authors:  Takuro Sakagami; David Beck; Kanji Uchida; Takuji Suzuki; Brenna C Carey; Koh Nakata; Gary Keller; Robert E Wood; Susan E Wert; Machiko Ikegami; Jeffrey A Whitsett; Maurizio Luisetti; Stella Davies; Jeffrey P Krischer; Alan Brody; Fred Ryckman; Bruce C Trapnell
Journal:  Am J Respir Crit Care Med       Date:  2010-03-11       Impact factor: 21.405

4.  An open-label trial of rituximab therapy in pulmonary alveolar proteinosis.

Authors:  M S Kavuru; A Malur; I Marshall; B P Barna; M Meziane; I Huizar; H Dalrymple; R Karnekar; M J Thomassen
Journal:  Eur Respir J       Date:  2011-04-08       Impact factor: 16.671

5.  [Classification of pulmonary alveolar proteinosis in newborns, infants, and children].

Authors:  F Brasch; K-M Müller
Journal:  Pathologe       Date:  2004-07       Impact factor: 1.011

6.  High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease.

Authors:  A Sergeeva; Y Ono; R Rios; J J Molldrem
Journal:  Leukemia       Date:  2008-01-24       Impact factor: 11.528

7.  Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis.

Authors:  Lindsey B Rosen; Alexandra F Freeman; Lauren M Yang; Kamonwan Jutivorakool; Kenneth N Olivier; Nasikarn Angkasekwinai; Yupin Suputtamongkol; John E Bennett; Vasilios Pyrgos; Peter R Williamson; Li Ding; Steven M Holland; Sarah K Browne
Journal:  J Immunol       Date:  2013-03-18       Impact factor: 5.422

Review 8.  Origin and ontogeny of lung macrophages: from mice to humans.

Authors:  Elza Evren; Emma Ringqvist; Tim Willinger
Journal:  Immunology       Date:  2019-12-04       Impact factor: 7.397

9.  Pulmonary alveolar proteinosis.

Authors:  Adrian Kwok Wai Chan; Angela Takano; Ann Ling Hsu; Su Ying Low
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

Review 10.  Rare lung disease II: pulmonary alveolar proteinosis.

Authors:  Stephen C Juvet; David Hwang; Thomas K Waddell; Gregory P Downey
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.